MedTrace Logo

Selective RPE Laser Treatment (SRT) for Various Macular Diseases

NCT00403884 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-01-13

No results posted yet for this study

Summary

In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens. The macular diseases to be treated are drusen maculopathy and geographic atrophy due to age-related macular degeneration as well as diabetic macular edema and central serous chorioretinopathy.

The beneficial effect in laser treatment is thought to be associated with the restoration of a new barrier of retinal pigment epithelium cells. If this theory is true, the destruction of the photoreceptors causing visual field defects would be only an unwanted and unnecessary side effect. Thus, SRT is able to avoid these unintentional side effects and to achieve the benefit by just treating the RPE.

In this study the clinical effect of SRT for these diseases is evaluated on a long-term basis.

Conditions

  • Age-Related Macular Degeneration
  • Diabetic Maculopathy
  • Central Serous Chorioretinopathy

Interventions

PROCEDURE

Selective RPE laser treatment

interventional SRT laser treatment

Sponsors & Collaborators

  • Dr. Werner Jackstaedt Foundation

    collaborator UNKNOWN

  • University of Regensburg

    lead OTHER

Principal Investigators

  • Carsten Framme, MD · University Eye Hospital Regensburg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-12-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403884 on ClinicalTrials.gov